StockWatch
·
Biotechnology: Pharmaceutical Preparations
Board MeetingNov 13, 2026, 08:31 AM

Kyntra Bio Q3 2026 Earnings Call Scheduled for November 16

AI Summary

Kyntra Bio, Inc. (Nasdaq: KYNB) has announced that it will release its third quarter 2026 financial results after market close on Monday, November 16. The company will host a conference call and webcast presentation on the same day at 5:00 PM Eastern Time to discuss these results and provide a business update, followed by a live Q&A session. Kyntra Bio is a biopharmaceutical company developing novel therapies in oncology and rare diseases, with products like Roxadustat and FG-3246 in various stages of development.

Key Highlights

  • Kyntra Bio, Inc. to announce third quarter 2026 financial results on Monday, November 16 after market close.
  • A conference call and webcast presentation will be held on November 16 at 5:00 PM Eastern Time.
  • Management will discuss financial results and provide a business update during the call.
  • A live Q&A session will follow the presentation.
  • Roxadustat is approved in Europe, Japan, China, and other countries for anemia in CKD patients.
  • FG-3246 (FOR46) is in Phase 2 development for metastatic castration-resistant prostate cancer.